Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3

Alexander Lesokhin, Ruben Niesvizky, Bertrand Arnulf, Sarah Larson, Christopher Strouse, Carlos Fernandez de Larrea, David Vesole, Yuya Nagai, Sharon T. Sullivan, Eric Leip, Andrea Viqueira, Nizar Bahlis

Blood (2025) 146 (Supplement 1): 2269.

https://doi.org/10.1182/blood-2025-2269

Published: 2025

Journal Articles

CD62L enrichment achieves robust expansion and memory phenotype post-infusion in patients with LBCL treated with rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate

Akil Merchant, Ben Harris, Lora Zhao, Sahithi Cheemalamarri, Sobha Potluri, Tahir Latif, Umar Farooq, Sarah Larson

Blood (2025) 146 (Supplement 1): 501.

https://doi.org/10.1182/blood-2025-501

Published: 2025

Journal Articles

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Blood (2025) 146 (Supplement 1): 97.

https://doi.org/10.1182/blood-2025-97

Published: 2025

Journal Articles

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Ciara Louise Freeman, Sarah Larson, Omar Nadeem, Nikhil Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu, Svenja Johanna Groeneveld, Sarah Johnston, Timothy Pulham, Sandy Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina Patel

Blood (2025) 146 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2025-4079

Published: 2025

Journal Articles

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma

Sarah Larson, Umar Farooq, Tahir Latif, Felix Mensah, Bradley Hunter, Stefan Ciurea, Nebu Koshy, Locke Bryan, Boyu Hu, William Clark, Hassaan Yasin, Yeonhee Kim, Greg Kaufman, Akil Merchant

Blood (2025) 146 (Supplement 1): 668.

https://doi.org/10.1182/blood-2025-668

Published: 2025

Journal Articles

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Blood (2025) 146 (Supplement 1): 697.

https://doi.org/10.1182/blood-2025-697

Published: 2025

Journal Articles

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Blood (2025) 146 (Supplement 1): 2302.

https://doi.org/10.1182/blood-2025-2302

Published: 2025

Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood (2025) 145 (3): 300–310.

https://doi.org/10.1182/blood.2024025746

Published: 2025

Includes: Supplemental data

Journal Articles

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Anupama Kumar, Aaron S Rosenberg, Michelle Padilla, Nina Shah, Lindsey Sirianni, Lin Liu, Yuwei Cheng, Emily Pittman, Dimitrios Tzachanis, Sarah Larson, Carolyn Mulroney, Edward D. Ball, Caitlin Costello

Blood (2022) 140 (Supplement 1): 4436–4437.

https://doi.org/10.1182/blood-2022-169838

Published: 2022

Journal Articles

Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study

Kerry A. Rogers, Ian W. Flinn, Deborah M. Stephens, Thomas J. Kipps, Sarah Larson, Carolyn McGarry, Nadia B. Hassounah, Liangke Connie Gou, Janghee Woo, John C. Byrd

Blood (2021) 138 (Supplement 1): 2631.

https://doi.org/10.1182/blood-2021-147775

Published: 2021

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia

Sanaz Ghafouri, MD, Christopher Walthers, PhD, Mobina Roshandell, MS, Brenda Ji, BS, Jacqueline Trent, Jia Ming Chen, PhD, Jacob Naparstek, Monica Mead, MD BS, John M. Timmerman, MD, Yvonne Chen, Sarah Larson, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-137630

Published: 2020

Journal Articles

Best Practices for Validation of Measurable Residual Disease Assessments By Multiparameter Flow Cytometry in Emerging Clinical Trials of Acute Myeloid Leukemia

Pavinder Kaur, Anil Pahuja, Kevin Nguyen, Pedro Marques Ramos, PhD, Ling Du, PhD, Jacqueline J Cloos, Maaike E Heidinga, Yvonne J.M Oussoren-Brockhoff, Angele Kelder, Xun Li, Sarah Larson, MD, Shabnam Tangri, Ghanashyam Sarikonda, Naveen Dakappagari

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137787

Published: 2020

Journal Articles

Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations

Mao Yu Peng, PhD, Yasmin Abaza, MD, Martina Mcdermott, PhD, Monica Mead, MD BS, Dennis J. Slamon, MD PhD, Sarah Larson, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141459

Published: 2020

Journal Articles

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, MD PhD, Antonio Jiménez-Velasco, MD, Sarah Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Yair Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin Regueira, MD, Jeffrey H. Lipton, MD PhD

Blood (2018) 132 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2018-99-116563

Published: 2018

Journal Articles

Efficacy and Mechanism of Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies

Monica Mead, MD BS, Erika Von Euw, PhD BS, Dylan Conklin, Ben Powell, PhD BS, Kanthinh Manivong, BS, Eileen Do, Dennis J. Slamon, MDPhD, Sarah Larson, MD

Blood (2015) 126 (23): 3702.

https://doi.org/10.1182/blood.V126.23.3702.3702

Published: 2015

Journal Articles

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari, MD, Saurabh Chhabra, MD, Saad Usmani, MD, Sarah Larson, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Cristina Gasparetto, MD, Beata Holkova, MD, Matthew Lunning, DO, Jason Valent, MD, Larry D. Anderson, Jr., MD PhD, Chatchada Karanes, MD, Long Kwei, PhD, Lipo Chang, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Kevin McDonagh, MD

Blood (2015) 126 (23): 377.

https://doi.org/10.1182/blood.V126.23.377.377

Published: 2015

Journal Articles

Pre-Clinical Development of Gene Modification of Hematopoietic Stem Cells with Chimeric Antigen Receptors for Cancer Immunotherapy

Laurel Christine Truscott, MD, Sarah Larson, MD, Amie Patel, Roy L. Kao, MD, Satiro N. De Oliveira, MD

Blood (2015) 126 (23): 4430.

https://doi.org/10.1182/blood.V126.23.4430.4430

Published: 2015

Journal Articles

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Todd A. Fehniger, MD/PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J. Siegel, MD, David D. Hurd, MD, Kristie A. Blum, MD, Andre Goy, MD, Timothy S. Fenske, MD, Amanda Cashen, MD, Nina D. Wagner-Johnston, MD, Kenneth R. Carson, MD, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 1623.

https://doi.org/10.1182/blood.V120.21.1623.1623

Published: 2012

Journal Articles

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J. Siegel, Amanda F. Cashen, Kristie A. Blum, Timothy S. Fenske, David D. Hurd, Andre Goy, Stephanie E. Schneider, Catherine R. Keppel, Nina D. Wagner-Johnston, Kenneth R. Carson, Nancy L. Bartlett

Blood (2011) 118 (19): 5119–5125.

https://doi.org/10.1182/blood-2011-07-362475

Published: 2011

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3

CD62L enrichment achieves robust expansion and memory phenotype post-infusion in patients with LBCL treated with rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia

Best Practices for Validation of Measurable Residual Disease Assessments By Multiparameter Flow Cytometry in Emerging Clinical Trials of Acute Myeloid Leukemia

Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Efficacy and Mechanism of Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Pre-Clinical Development of Gene Modification of Hematopoietic Stem Cells with Chimeric Antigen Receptors for Cancer Immunotherapy

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only